Group 1 - The company, Hangzhou Tian-Mu-Shan Pharmaceutical Co., Ltd., was established as a pilot unit for state-owned enterprise reform in October 1989 and has undergone several regulatory updates since then [2][3][4] - The registered capital of the company is RMB 121.78 million, and it operates as a permanent joint-stock company [4][5] - The company aims to develop a modern enterprise group with first-class economic benefits and products, focusing on pharmaceutical production and diversified development [3][4] Group 2 - The company has established a party organization to play a political core role and provide political guidance in its development [2] - The company’s business scope includes the production of various pharmaceutical forms, health foods, medical devices, and cosmetics, among others [3][4] Group 3 - The company issues shares in the form of stocks, with each share having a face value of RMB 1 [4][5] - The total number of shares issued by the company is 121,778,885, all of which are ordinary shares [4][5] Group 4 - The company is prohibited from providing financial assistance for others to acquire its shares, except under specific circumstances approved by the shareholders' meeting [5][6] - The company can reduce its registered capital following legal procedures and shareholder approval [6][7] Group 5 - The company’s shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [10][11] - Shareholders holding more than 5% of the shares must declare their holdings and any changes [8][9] Group 6 - The company’s shareholders' meeting is the authority of the company, responsible for electing directors, approving financial reports, and making significant corporate decisions [18][19] - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year [21][22]

Core Points - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., has obtained a new drug production license valid until August 24, 2030, ensuring compliance and continuity in operations [1][2] - The new license was issued by the Shaanxi Provincial Drug Administration due to the expiration of the previous license, which is a routine regulatory process [1][2] Company Information - The new drug production license number is 陕 20160073, and the company is located in Xi'an, Shaanxi Province [1] - The legal representative and responsible person for quality is Wang Yanling, while the production manager is Guo Jiangang [1] Production Scope - The company is authorized to produce a variety of pharmaceutical forms including plasters, ointments, granules, hard capsules, tablets, tinctures, and more across multiple production sites in Xi'an [1]

Core Points - The announcement confirms that nine companies, including Heilongjiang Guoyao Tianjiang Pharmaceutical Co., Ltd., have passed the on-site inspections and comply with the Good Manufacturing Practice (GMP) requirements as per the Drug Administration Law and related regulations [3][4] Group 1: Compliance and Inspections - Heilongjiang Guoyao Tianjiang Pharmaceutical Co., Ltd. is noted for its production lines for traditional Chinese medicine pieces, including various processing methods [3] - Heilongjiang Songhua Pharmaceutical Technology Co., Ltd. has passed inspections for its freeze-dried powder injection production lines [3] - Harbin Dayang Pharmaceutical Co., Ltd. has been inspected for its solid dosage forms, including tablets and capsules [3] Group 2: Production Facilities - Heilongjiang Zhenbao Island Pharmaceutical Co., Ltd. has been recognized for its oral liquid production lines and related processing facilities [3] - Heilongjiang Yibai Pharmaceutical Co., Ltd. has been inspected for its solid dosage forms and extraction processes [3] - Heilongjiang Daxinganling Liwo Pharmaceutical Co., Ltd. has passed inspections for its raw material drug production lines [3]

Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].

Core Viewpoint - The Heilongjiang Provincial Drug Administration announced the results of the GMP compliance inspections for 16 pharmaceutical companies, confirming their adherence to the 2010 revised Good Manufacturing Practice standards [3]. Group 1: Compliance Inspection Results - Heilongjiang Sanlian Pharmaceutical Co., Ltd. was inspected for its small-volume injection production line, specifically for anti-tumor drugs, and found compliant [3]. - Harbin Pharmaceutical Group's second factory was inspected for its granule and oral liquid production lines, confirming compliance [3]. - Heilongjiang Huabei Pharmaceutical Co., Ltd. was inspected for its solid dosage forms and traditional Chinese medicine extraction processes, and was found compliant [3]. Group 2: Inspection Details - The inspections were conducted between April and May 2025, with specific dates for each company listed [3]. - The inspection covered various production lines, including small-volume injections, oral liquids, and traditional Chinese medicine extracts [3]. - The results indicate a focus on ensuring quality and compliance within the pharmaceutical manufacturing sector in Heilongjiang Province [3].

Core Points - The company is Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd, established in 1993 and registered in Jilin Province, China [4][6][7] - The company aims to build a health industry chain and ecosystem, contributing to the modernization and internationalization of the national health industry while maximizing shareholder returns [9] - The registered capital of the company is RMB 966,494,707 [7] Chapter Summaries Chapter 1: General Principles - The company is established to protect the rights of shareholders, employees, and creditors, following the Company Law and Securities Law of the People's Republic of China [4] - The company has undergone several changes in its registration and licensing, including a name change to Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd in 2000 [6][7] Chapter 2: Business Objectives and Scope - The business objectives include serving human health and contributing to the health industry [9] - The business scope includes manufacturing various pharmaceutical forms, research and development of traditional Chinese medicine, and medical project investments [9] Chapter 3: Shares - The company issues shares in the form of stocks, with a total of 966,494,707 shares issued, all being ordinary shares [10][21] - The company follows principles of fairness and transparency in share issuance [10] Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights to dividends, attend meetings, and supervise company operations [16] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [25] Chapter 5: Board of Directors - The board of directors is responsible for the company's management and must act in the best interest of the company and its shareholders [18] - The company has provisions for independent directors and committees within the board [18] Chapter 6: Senior Management - Senior management includes the general manager, deputy general managers, and other key personnel [8] Chapter 7: Financial Accounting System, Profit Distribution, and Auditing - The company must adhere to a financial accounting system and undergo internal audits [8] Chapter 8: Notices and Announcements - The company is required to issue notices and announcements as per legal requirements [8] Chapter 9: Mergers, Divisions, Capital Increases, Reductions, Dissolution, and Liquidation - The company can merge, divide, increase or reduce capital, and dissolve according to legal procedures [8] Chapter 10: Amendments to the Articles - The company can amend its articles of association following the prescribed procedures [8] Chapter 11: Supplementary Provisions - The articles of association serve as a binding document for the company, shareholders, directors, and senior management [8]